Unimed Biotech
Molecular diagnostic testing
About Unimed Biotech
Unimeddx operates in the in-vitro diagnostics (IVD) market, specializing in the capture and analysis of circulating tumor cells (CTCs). These are tumor cells that detach from the primary tumor and enter the bloodstream, potentially leading to recurrence and metastasis. The company leverages a suite of innovative technologies to develop high-efficiency, high-throughput, and accurate IVD products. These products are designed for professional clinical testing and scientific research services, including genetic analysis, carrier screening, microbial identification, and cancer companion diagnostics. Unimeddx serves healthcare providers, research institutions, and laboratories, offering them advanced tools to improve diagnostic accuracy and patient outcomes. The business model revolves around the sale of IVD products and related services, generating revenue through product sales and service contracts.
Source: Dealroom company dataAt a glance
- Founded
- 2013
- Headquarters
- Huangpu, China
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
- HCHexi Capital
- BABasetra
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Unimed Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Unimed Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.